ABSTRACT
PURPOSE: The purpose of this study was to evaluate the role of glucose transporter in peritoneal glucose and fluid transport. METHODS: Male Sprague-Dawley rats were used. 5mL normal saline with(CB) and without(C) Cytochalasin B(1 muM) was intraperitoneally injected once. From the next day 25 mL commercial dialysis solutions containing 4.25% glucose was injected into the peritoneal cavity twice a day for 8 weeks in a half of each group(CB-IP, n=6 and C-IP, n=8). The other half of each group served as control without IP(C- Control, n=7 and CB-Control, n=7). A 2 hour dwell study was performed using dialysis solutions containing 4.25% glucose. Intraperitoneal volume(IPV) after 2 hours of dwell was measured and peritoneal fluid absorption rate(Qa) was calculated as RISA disappearance rate. Dialysate glucose amount remaining after 2hour dwell(DGA) was calculated and expressed as % of the initial value. RESULTS: IPV was significantly higher in CB than in C in both IP and Control. IPV was significantly lower in C-IP than in C-Control and CB-IP while it was similar between CB-Control and CB-IP. Qa was significantly higher in IP than in Control. DGR was significantly higher in CB than in C and in control than in IP. CONCLUSION: Longterm peritoneal exposure to high glucose dialysis solution increased peritoneal glucose absorption and decreased ultrafiltration volume in rat. A single IP use of glucose transporter inhibitor attenuated increased glucose absorption and decreased ultrafiltration after longterm peritoneal exposure to dialysate.
Subject(s)
Animals , Humans , Male , Rats , Absorption , Ascitic Fluid , Dialysis , Dialysis Solutions , Glucose Transport Proteins, Facilitative , Glucose , Peritoneal Cavity , Peritoneal Dialysis, Continuous Ambulatory , Rats, Sprague-Dawley , UltrafiltrationABSTRACT
This report dscribes the thymic carcinoid tumor behaved in a highly aggressive fashion metastasis. Anti-cancer chemotherapy was not effective, the patient died of progressive disease after three months of diagnosis.
Subject(s)
Humans , Bone Marrow , Carcinoid Tumor , Diagnosis , Drug Therapy , Neoplasm Metastasis , Pleural Effusion , Thymus GlandABSTRACT
Malignant fibrous histiocytoma (MFH) of the heart is a very rare disease. It is difficult to distinguish from myxoma which is most common benign cardiac tumor. Prognosis of malignant fibrous histiocytoma (MFH) of the heart is known to be fatal despite of medical and surgical treatment in contrast to benign tumors. A primary myxoid malignant fibrous histiocytoma of the left atrium was diagnosed in a 58 years old woman. The mass was removed incompletely by operation. The patient did not receive either chemotherapy or radiotherapy. However, the patient is still alive for more than fifteen months after the initial presentation. We report a case of malignant fi brous histiocytoma (MFH) with reviewing the current references.